Tanvex BioPharma, Inc. (6541.TW)
TWD 61.4
(-1.6%)
TWD 61.4
(-1.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.43 Billion | -1.33 Billion | -1.38 Billion | -1.78 Billion | -1.89 Billion | -1.6 Billion |
| Net Income | -2.13 Billion | -1.64 Billion | -1.54 Billion | -2.1 Billion | -2.27 Billion | -1.89 Billion |
| Depreciation & Amortization | 324.83 Million | 281.55 Million | 243.58 Million | 220.4 Million | 215.96 Million | 142.76 Million |
| Deferred income taxes | -920.8 Million | - | -41.75 Million | 967 Thousand | 61.32 Million | 38.12 Million |
| Stock-based compensation | 326.6 Million | 67.54 Million | 52.94 Million | 80.35 Million | 155.71 Million | 164.3 Million |
| Change in working capital | 39.99 Million | -49.02 Million | -51.07 Million | 14.94 Million | -10.24 Million | -7.25 Million |
| Other non-cash items | 932.66 Million | 7.18 Million | -47.53 Million | -85 Thousand | -47.21 Million | -49.99 Million |
| Investing Cash Flow | -83.57 Million | -97.35 Million | -24.68 Million | -243.29 Million | 1.81 Billion | -912.44 Million |
| Investments in PPE | -89.9 Million | -96.07 Million | -30.34 Million | -67.49 Million | -93.6 Million | -108.75 Million |
| Acquisitions | 6.33 Million | 1.81 Million | 6.17 Million | 170 Thousand | - | 3.4 Million |
| Investment purchases | -201.48 Million | 203.56 Million | 15.01 Million | -193.87 Million | - | -2.17 Billion |
| Sales/Maturities of investments | 201.48 Million | -203.56 Million | -15.01 Million | -170 Thousand | 1.91 Billion | 1.37 Billion |
| Other Investing Activities | -18.56 Million | -3.08 Million | -514 Thousand | 18.06 Million | -2.29 Million | -3.27 Million |
| Financing Cash Flow | 1.07 Billion | -123.29 Million | 1.59 Billion | 1.73 Billion | 914.15 Million | 2.14 Billion |
| Debt repayment | -127.66 Million | -130.52 Million | -93.11 Million | -94.86 Million | -68.18 Million | -1.39 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.2 Billion | 7.23 Million | 1.69 Billion | 1.7 Billion | 982.33 Million | 2.14 Billion |
| Other Financing Activities | -127.66 Million | -123.29 Million | 1.59 Billion | 121.97 Million | 914.15 Million | 2.14 Billion |
| Accounts receivables | -7.09 Million | 125 Thousand | -974 Thousand | -723 Thousand | -883 Thousand | -213 Thousand |
| Accounts payables | - | -125 Thousand | 974 Thousand | 723 Thousand | 883 Thousand | - |
| Inventory | 62.55 Million | -80.51 Million | -40.24 Million | 2.12 Million | -23.62 Million | -28.57 Million |
| Other working capital | -15.47 Million | 31.48 Million | -10.82 Million | 12.82 Million | 13.38 Million | 21.32 Million |
| Cash at beginning of period | 786.23 Million | 2.22 Billion | 2.06 Billion | 2.42 Billion | 1.63 Billion | 2.01 Billion |
| Cash at end of period | 380.75 Million | 786.23 Million | 2.22 Billion | 2.06 Billion | 2.42 Billion | 1.63 Billion |
| Capital Expenditure | -89.9 Million | -96.07 Million | -30.34 Million | -67.49 Million | -93.6 Million | -108.75 Million |
| Effect of forex changes on cash | 32.35 Million | 117.74 Million | -31.24 Million | -58.4 Million | -38.03 Million | -6.67 Million |
| Net cash flow / Change in cash | -405.48 Million | -1.43 Billion | 154.36 Million | -358.84 Million | 796.74 Million | -379.36 Million |
| Free Cash Flow | -1.52 Billion | -1.42 Billion | -1.41 Billion | -1.85 Billion | -1.99 Billion | -1.71 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -366.72 Million | -418.16 Million | -518.01 Million | -2.13 Billion | -504.94 Million | -505.49 Million |
| Depreciation & Amortization | 72.05 Million | 72.39 Million | 83.89 Million | 324.83 Million | 81.55 Million | 81.84 Million |
| Deferred income taxes | - | - | -144.85 Million | -920.8 Million | -5.9 Million | -3.67 Million |
| Stock-based compensation | -421 Thousand | -11.72 Million | -3.98 Million | 326.6 Million | 31.21 Million | 76.29 Million |
| Change in working capital | -46.32 Million | 63.03 Million | 10.05 Million | 39.99 Million | 82.05 Million | -45.91 Million |
| Other non-cash items | 159.1 Million | 133.41 Million | 156.53 Million | 932.66 Million | 5.67 Million | 3.64 Million |
| Investing Cash Flow | -159.25 Million | -35.54 Million | -20.23 Million | -83.57 Million | -50.11 Million | -6.45 Million |
| Investments in PPE | -30.98 Million | -35.69 Million | -22.13 Million | -89.9 Million | -34.35 Million | -9.36 Million |
| Acquisitions | 2000.00 | 133 Thousand | 383 Thousand | 6.33 Million | 261 Thousand | 5.69 Million |
| Investment purchases | -130.28 Million | - | -3.29 Million | -201.48 Million | - | - |
| Sales/Maturities of investments | - | - | 3.29 Million | 201.48 Million | - | - |
| Other Investing Activities | 2 Million | 16 Thousand | 1.51 Million | -18.56 Million | -16.02 Million | -2.78 Million |
| Financing Cash Flow | 1.01 Billion | 334.28 Million | -35.54 Million | 1.07 Billion | -22.57 Million | 1.16 Billion |
| Debt repayment | -375 Million | -375 Million | -39.11 Million | -127.66 Million | -30.26 Million | -25.94 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.43 Billion | 2.42 Million | 3.57 Million | 1.2 Billion | 7.68 Million | 1.19 Billion |
| Other Financing Activities | -41.14 Million | 377.42 Million | -39.11 Million | -127.66 Million | -30.26 Million | 1.16 Billion |
| Accounts receivables | -11.85 Million | 2.55 Million | -5.86 Million | -7.09 Million | 7.53 Million | -8.99 Million |
| Accounts payables | - | - | - | - | -7.53 Million | 8.99 Million |
| Inventory | -1.64 Million | -2.89 Million | 24.82 Million | 62.55 Million | 8.79 Million | -722 Thousand |
| Other working capital | -32.82 Million | 63.38 Million | -8.9 Million | -15.47 Million | 73.26 Million | -45.18 Million |
| Cash at beginning of period | 385.23 Million | 380.75 Million | 873.78 Million | 786.23 Million | 1.21 Billion | 426.51 Million |
| Cash at end of period | 910.32 Million | 385.23 Million | 380.75 Million | 380.75 Million | 873.78 Million | 1.21 Billion |
| Capital Expenditure | -30.98 Million | -35.69 Million | -22.13 Million | -89.9 Million | -34.35 Million | -9.36 Million |
| Effect of forex changes on cash | 4.48 Million | 201 Thousand | -20.87 Million | 32.35 Million | 36.94 Million | 24.04 Million |
| Net cash flow / Change in cash | 525.09 Million | 4.48 Million | -493.03 Million | -405.48 Million | -346.08 Million | 793.35 Million |
| Free Cash Flow | -370.47 Million | -330.14 Million | -438.5 Million | -1.52 Billion | -344.69 Million | -402.65 Million |
YALA
5203
SKBSY
BFS-PD
NVRO
002549